Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).
“We look forward to providing investors with an update on CNSide™, our novel assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system,” said Mr. Nall. “CNSide’s full commercial launch is now underway with the potential to provide critical information for the approximately 200,000 patients in the U.S. each year who have progression of their cancer to the central nervous system.”
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
Jody Cain, LHA Investor Relations